Streetbeat News

Equity Actions

CBRG

CBRGU

CBRGW

Chain Bridge I (NASDAQ:CBRGU, CBRG, CBRGW) has announced that it will redeem all of its outstanding Class A ordinary shares at a per-share price of approximately $10.80, effective as of the close of business on November 15, 2023. The decision comes as the company will not be able to consummate an initial business combination within the required time period. The company will cease all operations, except those required to wind up the business, and expects that the Nasdaq Stock Market will file a Form 25 with the U.S. Securities and Exchange Commission to delist its securities.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 8:01 pm

BYFC

Broadway Financial Corporation (BYFC) has repurchased 1,958,173 shares of its Class A Common Stock from the Federal Deposit Insurance Corporation (FDIC). The shares represented just under 4.0% of the company's total voting shares and over 2.6% of the company's total common equity. The shares were purchased at a price of $0.9095 per share. The company financed the purchase from cash on hand and the shares will be retired. The repurchase is seen as an important step in solidifying the company's long-term base of stockholders.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 7:45 pm

WAY

Healthcare company Waystar's initial public offering (IPO) has been delayed until December 2021 or possibly 2024, according to sources. The company was expected to begin marketing its shares this week ahead of a November listing.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 7:36 pm

CVS

A significant investor has taken a bearish stance on CVS Health (NYSE:CVS), with 100% of the detected 15 unusual trades being bearish. The trades include 9 puts worth $342,329 and 6 calls worth $196,561. The targeted price range for CVS Health over the last 3 months is from $45.0 to $75.0. The price of CVS is currently up 1.44% at $68.99, and the next earnings are expected to be released in 1 day.

Portfolio Pulse from Benzinga Insights

October 31, 2023 | 7:30 pm

BIDU

A significant bearish stance on Baidu (NASDAQ:BIDU) has been observed through unusual options activity. The sentiment among big-money traders is split between 46% bullish and 53% bearish. The whales have been targeting a price range from $105.0 to $140.0 for Baidu over the last 3 months. Currently, BIDU's price is down -1.99% at $104.06. Benchmark has downgraded its action to Buy with a price target of $210, while JP Morgan maintains their Overweight rating with a price target of $185.

Portfolio Pulse from Benzinga Insights

October 31, 2023 | 7:02 pm

DKNG

MGM

NBA star James Harden has been traded from the Philadelphia 76ers to the Los Angeles Clippers, a move that has significantly impacted the sports betting odds for the 2023-2024 NBA season. The trade has boosted the Clippers' odds of winning the NBA Championship from +1700 to +1200 at DraftKings Inc (NASDAQ:DKNG), and from +2200 to +1300 at BetMGM, a joint venture of MGM Resorts International (NYSE:MGM) and Entain. The 76ers' odds also slightly improved from +1900 to +1800.

Portfolio Pulse from Chris Katje

October 31, 2023 | 6:40 pm

FCX

A significant bearish stance has been taken on Freeport-McMoRan (NYSE:FCX) by a large investor or institution, as indicated by unusual options activity. The sentiment among these big-money traders is 28% bullish and 71% bearish. The whales have been targeting a price range from $30.0 to $40.0 for FCX over the last 3 months. The current price of FCX is down -1.13% at $33.66. Morgan Stanley, BMO Capital, and JP Morgan have maintained their ratings on FCX with price targets of $41, $45, and $42 respectively.

Portfolio Pulse from Benzinga Insights

October 31, 2023 | 6:31 pm

BLRX

BioLineRx has entered into an exclusive license agreement for motixafortide in Asia, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 6:21 pm

BFRI

Biofrontera has announced a $4.5 million registered direct offering, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 6:12 pm

SLS

SELLAS Life Sciences has announced a $4 million registered direct offering, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 6:12 pm